Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896886003> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W2896886003 abstract "Background Patients with clinically amyopathyc dermatomyositis (CADM) with MDA5 positive autoantibodies may develop a severe pulmonary syndrome with rapidly progressive interstitial lung disease (RP-ILD) with a bad prognosis and high mortality. Objectives To analyse the efficacy of a therapeutic protocol that includes hemoperfusion with polymyxin B (PMX-HP) in addition to immunosuppressive treatment with tacrolimus and glucocorticoids, plasmapheresis and intravenous immunoglobulin (IVIG). Methods We retrospectively analysed 12 (10 male) patients diagnosed with anti-MDA5 (+) CADM associated RP-ILD between 1983 and 2018. Anti-MDA5 antibodies were determined by ELISA and confirmed by blot. RP-ILD was defined as a worsening of radiologic interstitial changes with progressive dyspnoea and hypoxemia within 1 month after the onset of respiratory symptoms. From 2014 to 2018, patients (Group 1) were treated with the following protocol: pulses of methylprednisolone (500 mg/day for 3 consecutive days), tacrolimus 2 mg/12 hour, PMX-HP (Toraymyxin 20R, Toray Medical Co., Tokyo, Japan) at a flow of 100 ml/h for 3 hour once daily on two successive days, and a plasmapheresis scheme with replacement of 3.5 l of seroalbumin 5% followed by IVIG infusion (0.4 mg/kg) during 3 consecutive days and then in alternate days for 7 days more. A comparison was performed with anti-MDA5 (+) CADM associated RP-ILD patients from a historical group (Group 2). PaO2/FiO2 (P/F) ratio was measured before and after PMX therapy. A composite endpoint that included mortality due to respiratory failure or lung transplantation was defined. Differences between pre- and post-PMX P/F values were evaluated using paired sample t-test. Results Mean (SD) age at diagnosis was 49 (3.5) yrs, with a mean (SD) follow-up of 13 (3.9) months. Comparison between both Groups showed that 3 out of 6 (50%) patients from the Group 1 in comparison with 5 out of 6 (83.3%) from the historical group (Group 2) reached the composite end point. Mean (CI 95%) values of P/F after PMX treatment showed a significantly improvement when compared with the pre-PMX values (240 [85–396] vs. 125,60–189 p=0.038) Conclusions Our protocol seems to be useful at some extent in anti-MDA5 (+) CADM associated RP-ILD patients. A transient but significant improvement can be attributed to PMX-HP. Adsorption and elimination of inflammatory cytokines, mediators and activated leukocytes, as well as anti-MDA5 antibodies could be the rationale of its efficacy. Disclosure of Interest None declared" @default.
- W2896886003 created "2018-10-26" @default.
- W2896886003 creator A5006407713 @default.
- W2896886003 creator A5030856020 @default.
- W2896886003 creator A5042393755 @default.
- W2896886003 creator A5050342854 @default.
- W2896886003 creator A5051009231 @default.
- W2896886003 creator A5059437760 @default.
- W2896886003 creator A5065674517 @default.
- W2896886003 creator A5067915727 @default.
- W2896886003 creator A5077547848 @default.
- W2896886003 creator A5089128695 @default.
- W2896886003 date "2018-06-01" @default.
- W2896886003 modified "2023-10-17" @default.
- W2896886003 title "SAT0475 Anti-mda5 (+) clinically amyopathic dermatomyositis-associated rapidly progressive interstitial lung disease: role of hemoperfusion with polymyxin" @default.
- W2896886003 doi "https://doi.org/10.1136/annrheumdis-2018-eular.2594" @default.
- W2896886003 hasPublicationYear "2018" @default.
- W2896886003 type Work @default.
- W2896886003 sameAs 2896886003 @default.
- W2896886003 citedByCount "0" @default.
- W2896886003 crossrefType "proceedings-article" @default.
- W2896886003 hasAuthorship W2896886003A5006407713 @default.
- W2896886003 hasAuthorship W2896886003A5030856020 @default.
- W2896886003 hasAuthorship W2896886003A5042393755 @default.
- W2896886003 hasAuthorship W2896886003A5050342854 @default.
- W2896886003 hasAuthorship W2896886003A5051009231 @default.
- W2896886003 hasAuthorship W2896886003A5059437760 @default.
- W2896886003 hasAuthorship W2896886003A5065674517 @default.
- W2896886003 hasAuthorship W2896886003A5067915727 @default.
- W2896886003 hasAuthorship W2896886003A5077547848 @default.
- W2896886003 hasAuthorship W2896886003A5089128695 @default.
- W2896886003 hasBestOaLocation W28968860031 @default.
- W2896886003 hasConcept C126322002 @default.
- W2896886003 hasConcept C141071460 @default.
- W2896886003 hasConcept C159654299 @default.
- W2896886003 hasConcept C203014093 @default.
- W2896886003 hasConcept C2776888751 @default.
- W2896886003 hasConcept C2777543607 @default.
- W2896886003 hasConcept C2777714996 @default.
- W2896886003 hasConcept C2778063415 @default.
- W2896886003 hasConcept C2778751314 @default.
- W2896886003 hasConcept C2778842783 @default.
- W2896886003 hasConcept C2780372218 @default.
- W2896886003 hasConcept C2781123077 @default.
- W2896886003 hasConcept C2781448352 @default.
- W2896886003 hasConcept C2909675724 @default.
- W2896886003 hasConcept C2911091166 @default.
- W2896886003 hasConcept C42219234 @default.
- W2896886003 hasConcept C71924100 @default.
- W2896886003 hasConcept C90924648 @default.
- W2896886003 hasConceptScore W2896886003C126322002 @default.
- W2896886003 hasConceptScore W2896886003C141071460 @default.
- W2896886003 hasConceptScore W2896886003C159654299 @default.
- W2896886003 hasConceptScore W2896886003C203014093 @default.
- W2896886003 hasConceptScore W2896886003C2776888751 @default.
- W2896886003 hasConceptScore W2896886003C2777543607 @default.
- W2896886003 hasConceptScore W2896886003C2777714996 @default.
- W2896886003 hasConceptScore W2896886003C2778063415 @default.
- W2896886003 hasConceptScore W2896886003C2778751314 @default.
- W2896886003 hasConceptScore W2896886003C2778842783 @default.
- W2896886003 hasConceptScore W2896886003C2780372218 @default.
- W2896886003 hasConceptScore W2896886003C2781123077 @default.
- W2896886003 hasConceptScore W2896886003C2781448352 @default.
- W2896886003 hasConceptScore W2896886003C2909675724 @default.
- W2896886003 hasConceptScore W2896886003C2911091166 @default.
- W2896886003 hasConceptScore W2896886003C42219234 @default.
- W2896886003 hasConceptScore W2896886003C71924100 @default.
- W2896886003 hasConceptScore W2896886003C90924648 @default.
- W2896886003 hasLocation W28968860031 @default.
- W2896886003 hasOpenAccess W2896886003 @default.
- W2896886003 hasPrimaryLocation W28968860031 @default.
- W2896886003 hasRelatedWork W1984949703 @default.
- W2896886003 hasRelatedWork W2031872886 @default.
- W2896886003 hasRelatedWork W2032907954 @default.
- W2896886003 hasRelatedWork W2349456791 @default.
- W2896886003 hasRelatedWork W2353601520 @default.
- W2896886003 hasRelatedWork W2362942554 @default.
- W2896886003 hasRelatedWork W2387917475 @default.
- W2896886003 hasRelatedWork W2477318394 @default.
- W2896886003 hasRelatedWork W2767125448 @default.
- W2896886003 hasRelatedWork W2779714376 @default.
- W2896886003 hasRelatedWork W2894919341 @default.
- W2896886003 hasRelatedWork W2899723038 @default.
- W2896886003 hasRelatedWork W2969270000 @default.
- W2896886003 hasRelatedWork W2980405877 @default.
- W2896886003 hasRelatedWork W3030883980 @default.
- W2896886003 hasRelatedWork W3092342791 @default.
- W2896886003 hasRelatedWork W3118353160 @default.
- W2896886003 hasRelatedWork W3119481005 @default.
- W2896886003 hasRelatedWork W3154983483 @default.
- W2896886003 hasRelatedWork W3206130372 @default.
- W2896886003 isParatext "false" @default.
- W2896886003 isRetracted "false" @default.
- W2896886003 magId "2896886003" @default.
- W2896886003 workType "article" @default.